Medlock Holmes enters a laboratory containing a brain that appears, at first glance, entirely normal.
There is no tumour.
No haemorrhage.
No obvious area of destruction.
Nothing resembling the unmistakable lesions seen in many neurological diseases.
Yet Holmes knows that normal appearance does not mean normal function.
He begins his investigation at the microscopic level.
Within the prefrontal cortex, the number of neurons is largely preserved, but the space between them has changed. Dendritic branches are less elaborate. Synaptic spines are reduced. The neuropil-the dense forest of axons, dendrites, and synaptic connections-has thinned. The architecture remains standing, but many of the bridges between cells have disappeared.
Similar clues emerge in the hippocampus and thalamus. Volumes may be modestly reduced, pyramidal cells smaller, and connectivity altered. The ventricles are often enlarged, yet these changes are subtle and nonspecific. Schizophrenia does not appear to destroy the brain in the manner of a classic neurodegenerative disorder. It seems instead to alter how neural systems are assembled, maintained, and connected.
Holmes then opens the chamber of neurotransmission.
For decades, dopamine was treated as the principal culprit. The modern picture is more complex. Subcortical dopamine synthesis and release are increased and closely linked with positive psychotic symptoms, while prefrontal dopamine activity may be reduced, contributing to cognitive dysfunction. Dopamine remains central, but it no longer stands alone.
Glutamate provides another vital clue. Reduced NMDA-receptor function can produce a syndrome resembling schizophrenia, including positive, negative, and cognitive symptoms. Postmortem findings suggest alterations in NMDA and AMPA receptor components across the cortex, hippocampus, and thalamus.
GABAergic inhibition is also disturbed. Reduced expression of GAD67, particularly in parvalbumin interneurons of the prefrontal cortex, may impair the timing and synchronisation of cortical networks. Acetylcholine receptors, both nicotinic and muscarinic, are reduced in several brain regions, potentially contributing to difficulties with attention, memory, and sensory processing.
Holmes notices that each system regulates the others.
Dopamine affects glutamate.
Glutamate drives GABA.
Adenosine modulates both dopamine and glutamate.
Acetylcholine shapes cognition and network activity.
Schizophrenia is therefore not a simple chemical excess or deficiency. It is a disturbance of coordinated signalling across an interconnected network.
The investigation moves deeper into the cell.
Mitochondria appear smaller or less numerous in some studies. Glycolysis, the tricarboxylic acid cycle, and oxidative phosphorylation show signs of dysregulation. Neurons may be receiving less efficient energy support precisely when complex signalling demands are greatest. The disorder may therefore involve not only faulty communication but also an impaired capacity to power that communication.
Holmes next enters the developmental wing of the laboratory.
Here the clues stretch across decades. Genetic vulnerability interacts with infection, nutrition, obstetric complications, cannabis exposure, and other environmental influences. Epigenetic mechanisms may alter gene expression without changing the DNA sequence itself, creating a biological record of environmental exposure.
Adolescent synaptic pruning becomes especially important. The healthy brain produces an abundance of connections and later removes those it no longer needs. In schizophrenia, this pruning may become excessive or poorly regulated, leaving certain cortical circuits underconnected. Myelination, neuronal migration, dendritic spine formation, and interneuron development may also be affected.
Finally, Holmes examines the immune chamber. Microglia, astrocytes, cytokines, and complement pathways suggest that inflammation may contribute to pathology in at least some people. Yet the evidence remains incomplete. The challenge is to distinguish primary disease mechanisms from downstream compensation, medication effects, and consequences of chronic illness.
By the end of the investigation, Holmes reaches a unifying conclusion.
Schizophrenia is not caused by one damaged region, one neurotransmitter, or one molecular defect.
It is increasingly understood as a disorder of connectivity.
The pathology may begin in development, appear in synapses, spread through circuits, disturb neurotransmission, impair cellular energy, and alter the relationship between brain and environment.
The brain is not broken like a machine with a missing gear.
It is more like an orchestra whose instruments remain present, but whose timing, communication, and shared score have fallen out of alignment.
Key Takeaways
Schizophrenia has no single identifiable neuropathological lesion.
Macroscopic brain appearance is often normal, with only subtle structural and cellular abnormalities.
Commonly implicated regions include the prefrontal cortex, hippocampus, thalamus, temporal cortex, and basal ganglia.
Enlarged lateral and third ventricles are frequently reported but are not diagnostically specific.
Reduced grey-matter volume appears to reflect smaller neurons and reduced neuropil rather than widespread neuronal loss.
Dendritic spine density is reduced in layer III of the prefrontal and temporal cortices.
Schizophrenia is not regarded as a classic neurodegenerative disease because overt neuron loss, gliosis, and neurofibrillary pathology are generally absent.
Subcortical dopamine synthesis and release are increased and relate strongly to positive psychotic symptoms.
Prefrontal dopaminergic hypoactivity may contribute to cognitive and negative symptoms.
Glutamatergic dysfunction, particularly NMDA-receptor hypofunction, may help explain positive, negative, and cognitive features.
Reduced GAD67 expression and parvalbumin-interneuron dysfunction indicate impaired GABAergic inhibition.
Nicotinic and muscarinic acetylcholine receptor abnormalities may contribute to impaired cognition and sensory processing.
Adenosine may influence schizophrenia by regulating both glutamate and dopamine systems.
Bioenergetic abnormalities involve glycolysis, the TCA cycle, oxidative phosphorylation, and mitochondrial function.
Schizophrenia is increasingly conceptualised as a neurodevelopmental disorder.
Potential developmental mechanisms include abnormal neuronal migration, excessive synaptic pruning, impaired spinogenesis, and altered myelination.
Epigenetic mechanisms may link environmental exposure with altered gene expression.
Inflammatory and immune processes may contribute to pathology in a subgroup of patients.
Findings from postmortem studies must be interpreted cautiously because of medication effects, tissue quality, illness duration, and disease heterogeneity.
The most coherent emerging model is schizophrenia as a disorder of connectivity across cellular, synaptic, and circuit levels.
